Gain Therapeutics, Inc. (GANX)
GANX moved a median of -1.05% 30 minutes after news, and -0.49% by the close. How GANX actually reacts to news — the realized, point-in-time move the market made, measured across 215 labeled events over the last three years with zero look-ahead.
GANX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.33% | 33% | 211 |
| 30-min | -1.05% | 37% | 214 |
| 60-min | -0.43% | 43% | 214 |
| to close | -0.49% | 43% | 212 |
| Middle 50% of GANX reactions | -2.77% to +1.37% |
|---|---|
| Median reaction (30-min) | -1.05% |
| Measured reactions | 215 |
Half of all Gain Therapeutics, Inc. news events land between -2.77% and +1.37% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when GANX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to GANX's baseline. Nothing else.
Recent GANX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Gain Therapeutics to Attend the 2026 Maxim Growth Summit | Press release | GlobeNewswire | -1.21% | -2.71% | |
| Form 8-K Gain Therapeutics, Inc. For: Oct 01 | SEC filing · Form 8-K | SEC EDGAR | -0.86% | -1.15% | |
| Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration | Press release | GlobeNewswire | -0.86% | -1.15% | |
| Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders | Press release | GlobeNewswire | +1.24% | +1.76% | |
| Form 8-K Gain Therapeutics, Inc. For: Sep 22 | SEC filing · Form 8-K | SEC EDGAR | -2.29% | -4.00% | |
| Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference | Press release | GlobeNewswire | -0.56% | +0.56% | |
| Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference | Press release | GlobeNewswire | -1.50% | -4.75% | |
| Form 10-Q Gain Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.99% | +5.47% | |
| Form 8-K Gain Therapeutics, Inc. For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | +1.99% | +5.47% | |
| Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update | Press release | GlobeNewswire | +2.09% | +15.73% | |
| Form 8-K Gain Therapeutics, Inc. For: Jul 16 | SEC filing · Form 8-K | SEC EDGAR | -1.18% | -1.77% | |
| Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update | Press release | GlobeNewswire | -1.18% | -1.77% | |
| Form 8-K Gain Therapeutics, Inc. For: Jun 29 | SEC filing · Form 8-K | SEC EDGAR | +1.03% | +4.10% | |
| Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease | Press release | GlobeNewswire | +1.03% | +4.10% | |
| Form 8-K Gain Therapeutics, Inc. For: Jun 24 | SEC filing · Form 8-K | SEC EDGAR | -1.14% | +1.74% | |
| Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit | Press release | GlobeNewswire | +3.70% | +1.24% | |
| Form 8-K Gain Therapeutics, Inc. For: May 26 | SEC filing · Form 8-K | SEC EDGAR | -1.59% | -3.70% | |
| Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026 | Press release | GlobeNewswire | -1.59% | -3.70% | |
| Form 10-Q Gain Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.18% | +0.00% | |
| Form 8-K Gain Therapeutics, Inc. For: May 11 | SEC filing · Form 8-K | SEC EDGAR | +1.18% | +0.00% | |
| Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update | Press release | GlobeNewswire | -2.70% | -1.62% | |
| Form ARS Gain Therapeutics, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.27% | -5.38% | |
| Form DEF 14A Gain Therapeutics, Inc. For: Jun 24 | SEC filing · Form DEF | SEC EDGAR | -0.27% | -5.38% | |
| Form DEFA14A Gain Therapeutics, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -0.27% | -5.38% | |
| Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026 | Press release | GlobeNewswire | -0.52% | +2.60% | |
| Form 10-K Gain Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +2.10% | -3.68% | |
| Form 8-K Gain Therapeutics, Inc. For: Mar 26 | SEC filing · Form 8-K | SEC EDGAR | +2.10% | -3.68% | |
| Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update | Press release | GlobeNewswire | +0.51% | -3.08% | |
| Gain Therapeutics to Present at the 38th Annual ROTH Conference | Press release | GlobeNewswire | -0.53% | +2.63% | |
| Form 8-K Gain Therapeutics, Inc. For: Mar 18 | SEC filing · Form 8-K | SEC EDGAR | -14.00% | -22.00% | |
| Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026 | Press release | GlobeNewswire | -14.00% | -22.00% | |
| Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update | Press release | GlobeNewswire | -3.17% | -3.17% | |
| Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference | Press release | GlobeNewswire | +0.24% | +4.42% | |
| Form 8-K Gain Therapeutics, Inc. For: Feb 03 | SEC filing · Form 8-K | SEC EDGAR | +0.56% | -1.68% | |
| Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week | Press release | GlobeNewswire | -1.15% | -8.02% | |
| Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287 | Press release | GlobeNewswire | -2.35% | -14.43% | |
| Form 8-K Gain Therapeutics, Inc. For: Dec 18 | SEC filing · Form 8-K | SEC EDGAR | -9.91% | -36.26% | |
| Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s Disease | Press release | GlobeNewswire | -9.91% | -36.26% | |
| Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease | Press release | GlobeNewswire | +8.39% | +20.80% | |
| Form S-8 Gain Therapeutics, Inc. | SEC filing · Form S-8 | SEC EDGAR | -2.18% | +5.74% | |
| Form 8-K Gain Therapeutics, Inc. For: Nov 28 | SEC filing · Form 8-K | SEC EDGAR | -1.72% | -7.16% | |
| Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025 | Press release | GlobeNewswire | -0.18% | +3.64% | |
| Form 10-Q Gain Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -4.44% | — | |
| Form 8-K Gain Therapeutics, Inc. For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | -4.44% | — | |
| Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update | Press release | GlobeNewswire | -5.47% | +1.72% | |
| Form S-3/A Gain Therapeutics, Inc. | SEC filing · Form S-3 | SEC EDGAR | -1.43% | +18.57% | |
| Gain Therapeutics to Present at Neuroscience 2025 | Press release | GlobeNewswire | -0.78% | -3.30% | |
| Gain Therapeutics to Attend the 2025 Maxim Growth Summit | Press release | GlobeNewswire | +1.07% | -2.69% | |
| Form 8-K Gain Therapeutics, Inc. For: Oct 14 | SEC filing · Form 8-K | SEC EDGAR | +3.03% | -5.56% | |
| Form 8-K Gain Therapeutics, Inc. For: Oct 06 | SEC filing · Form 8-K | SEC EDGAR | -2.83% | -7.08% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the GANX section they belong to.
Where else GANX is measured.
GANX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Gain Therapeutics, Inc.'s median reaction calculated?
Every labeled GANX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 215 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 37% of GANX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does GANX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.